Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling



Status:Recruiting
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:15 - Any
Updated:2/1/2019
Start Date:June 2014
End Date:February 2020
Contact:Preethi Prasad
Email:pprasad@CareDx.com
Phone:415-287-2558

Use our guide to learn which trials are right for you!

Utility of Donor-Derived Cell-free DNA in Association With Gene-Expression Profiling (AlloMap®) in Heart Transplant Recipients (D-OAR)

Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in
association with the measurement of AlloMap, a non-invasive gene expression test to aid in
heart transplant management.

AlloMap Molecular Expression Testing is performed in a single laboratory, assessing the gene
expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). Per FDA
labeling, AlloMap Testing is "intended to aid in the identification of heart transplant
recipients with stable allograft function who have a low probability of moderate/severe acute
cellular rejection (ACR) at the time of testing in conjunction with standard clinical
assessment." AlloMap is the only non-invasive, blood test method recommended in the
International Society for Heart and Lung Transplantation (ISHLT) guidelines for surveillance
of heart transplant recipients for rejection. More than 52,000 commercial AlloMap tests from
more than 12,000 patients have been reported by the XDx Reference Laboratory in Brisbane,
California, which is certified under the Clinical Laboratory Improvement Amendment (CLIA) of
1988 and accredited by the College of American Pathologists.

In 2013, a registry study named OAR was initiated to follow long-term outcomes in allograft
recipients receiving commercial AlloMap testing for surveillance (NCT01833195). The current
objective is to enroll volunteers who are participating in the OAR registry(1) to
co-participate in this observational sub-study, named D-OAR, in order to study a new
biomarker, dd-cfDNA.

dd-cfDNA has been proposed as a marker for cellular injury caused by rejection(2, 3). Because
dd-cfDNA and the AlloMap test measure different signals in the blood, a combination of the
two approaches could be additive since AlloMap is a measure of host immune response and
dd-cfDNA monitors graft injury.

The dd-cfDNA measurement is intended for the quantitative detection of plasma dd-cfDNA as a %
of the total plasma cell-free DNA. Its utility as a surveillance tool in the management of
heart transplant recipients is being investigated.

This is an observational sub-study for subjects who are co-enrolled to participate in the
Outcomes AlloMap Registry (OAR). Prior to implementation of the amendment dated September 15,
2016, blood specimens were collected for assay of dd-cfDNA levels at each visit that occurred
for AlloMap testing, per the OAR Study. As stated in the OAR study, the regular surveillance
schedule for testing with AlloMap is determined by each participating center's standard of
care. After this protocol amendment, the existing patients will no longer have routine
dd-cfDNA specimens drawn to be paired with their standard of care AlloMap. The dd-cfDNA
specimen will be drawn only when the patient is scheduled for a for-cause biopsy. New
patients may be enrolled any time post-transplant as long as they have not had more than 1
prior AlloMap. These patients will also only undergo routine AlloMap testing as per
participating center's standard of care and dd-cfDNA specimen will be drawn when the patient
is scheduled for a for-cause biopsy. An AlloMap sample will be drawn for research use along
with the dd-cfDNA specimen at the time of the for-cause biopsy where the center's
infrastructure permits. An additional two follow-up dd-cfDNA specimens will be collected in
the patients that undergo a for-cause biopsy, and are being treated for rejection and/or
graft dysfunction, as per their standard of care schedule. The two follow-up visits will not
be paired with a research use AlloMap and will be performed within 8 weeks after the for
cause event. If a patient returns for another for-cause biopsy, the center may opt to collect
another research AlloMap and dd-cfDNA specimen, and two follow-up dd-cfDNA specimens.

Inclusion Criteria

1. Any heart transplant recipient eligible for initiation and participation in the
Outcomes AlloMap Registry (OAR) Study of regular AlloMap testing.

2. Patients can be enrolled any time as long as they have not had more than 1 prior
AlloMap.

3. Written informed consent must be obtained prior to study enrollment. Exclusion
Criteria

1. Pregnant Women.
We found this trial at
28
sites
3310 Live Oak St
Dallas, Texas 75204
(214) 820-2687
Principal Investigator: Shelley Hall, MD
Baylor Research Institute Baylor Research Institute (BRI) is a dedicated research center for finding prevention...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Robert Cole, MD
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: Jayant Raikhelkar, MD
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Principal Investigator: Eugene DePasquale, MD
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
1 Tampa General Cir
Tampa, Florida 33606
(813) 844-7000
Principal Investigator: Peter Berman, MD
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Monica Colvin, MD
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Beverly Hills, California 90211
Principal Investigator: Jon Kobashigawa, MD
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Randall Starling, MD
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Principal Investigator: Sitaramesh Emani, MD
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
Principal Investigator: Pradeep Mammen, MD
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Hollywood, Florida 33021
Principal Investigator: Ioana Dumitru, MD
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Andrew Civitello, MD
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46290
Principal Investigator: Ashwin Ravichandran, MD
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Kansas City, Missouri
Principal Investigator: Andrew Kao, MD
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
Principal Investigator: Navin Rajagopalan, MD
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
?
mi
from
Lexington, KY
Click here to add this to my saved trials
2900 W Oklahoma Ave
Milwaukee, Wisconsin 53215
414-649-6000
Principal Investigator: Nasir Sulemanjee, MD
Aurora St. Luke's Medical Center At Aurora St. Luke's Medical Center, you'll find remarkable treatment...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Murray, Utah 84143
Principal Investigator: Abdallah G Kfoury, MD
?
mi
from
Murray, UT
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Selim Krim, MD
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Sean Pinney, MD
?
mi
from
New York, NY
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Farhana Latif, MD
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Oklahoma City, Oklahoma
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
3301 Lancaster Avenue
Philadelphia, Pennsylvania 19102
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
320 E North Ave
Pittsburgh, Pennsylvania 15212
(412) 359-3131
Principal Investigator: Manreet Kanwar, MD
Allegheny General Hospital At Allegheny General Hospital, our physicians and healthcare staff have earned an...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
Principal Investigator: Michael Shullo, PharmD
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Principal Investigator: Keyur Shah, MD
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Gregory Ewald, MD
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Principal Investigator: Kiran Khush, MD
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials